Advanced Search

 

Study ID Status Title Patient Level Data
208136/018 Completed Study to evaluate immunogenicity and safety of GSK Biologicals’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Biologicals’ Priorix™ and Varilrix™ vaccines Study Listed on ClinicalStudyDataRequest.com
208136/019 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals’ measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/022 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Biologicals' measles-mumps-rubella vaccine and varicella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/038 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines Study Listed on ClinicalStudyDataRequest.com
208136/039 Completed Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®. Study Listed on ClinicalStudyDataRequest.com
208136/040 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines Study Listed on ClinicalStudyDataRequest.com
208136/041 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines Study Listed on ClinicalStudyDataRequest.com
208139/053 Completed Open, multicentric, post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine (TRITANRIX-HB) injected in healthy infants according to theprescribing information Study Listed on ClinicalStudyDataRequest.com
208139/054 Completed An open randomised study in healthy infants vaccinated at birth with Engerix™-B (10µg) to evaluate the immunogenicity and the reactogenicity of the following GlaxoSmithKline (GSK) Biologicals’ vaccines: 1) combined DTP-HB vaccine (10µg HBsAg), 2) combined DTP-HB vaccine (5µg HBsAg), 3) simultaneous administration of Engerix™-B (10µg) vaccine in right thigh and whole-cell DTP vaccine in left thigh, when administered at 2, 4 and 6 months of age Study Listed on ClinicalStudyDataRequest.com
208140/005p Completed Immunogenicity and reactogenicity of GSK’s DTPa-HBV vaccine and GSK’s Hib vaccine, when administered simultaneously in 2 separate injections or in one single injection, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months
208140/020 Completed Immunogenicity & reactogenicity study of GSK’s DTPa-HBV & dtpa-HBV vaccines when administered with GSK’s Hib vaccine, either mixed and given in 1 single injection or given in 2 concomitant injections, as a booster vaccination at 15 to 22 months to healthy children, previously primed with a 3 doses of DTPa-HBV
208140/032 Completed Open clinical study of the immunogenicity and reactogenicity of SB Biologicals’ DTPa-HBV vaccine, when coadministered with SB Biologicals’ Hib vaccine in 2 concomitant injections into opposite limbs, as a primary vaccination course in healthy infants aged 2, 4 and 6 months, followed by a booster at 18 months
208140/038 Completed Immunogenicity and reactogenicity study of GSK’s DTPa HBV and Hib, either mixed or given in 2 concomitant injections, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months
208141/001 Completed An open study in healthy Herpes simplex virus (HSV)-positive adults to evaluate the safety of GSK Biologicals’ candidate gD vaccine, with or without 3D MPL
208141/002 Completed Study in healthy HSV positive and HSV negative adults to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' herpes simplex (gD) candidate vaccine with or without 3D-MPL adjuvant administered according to a 0,1, 6 month schedule.
208141/004 Completed A feasibility study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' Herpes simplex candidate vaccine (gD2t), with Monophosphoryl Lipid A (MPL) and with or without Tween in initially HSV-seronegative subjects.
208141/005 Completed A placebo-controlled study to evaluate the efficacy of SmithKline Beecham Biologicals’ herpes simplex candidate vaccine (gD2t) with MPL (Monophosphoryl Lipid A) to prevent genital herpes disease in healthy consorts of subjects with genital herpes disease.
208141/006 Completed A double-blind, randomised study to evaluate the reactogenicity and immunogenicity of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccines (gD2t) with MPL (Monophosphoryl Lipid A), (with or without tween) in healthy HSV-seropositive subjects.
208141/008 Completed An open randomised controlled study to evaluate in initially HSV-seronegative subjects, the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' Herpes simplex candidate vaccine (gD2t-MPL-QS21) with gD2t-Alum-MPL as control.
208141/009 Completed An open, randomised controlled study to evaluate - in HSV-seropositive subjects - the safety, reactogenicity and immunogenicity of SmithKline Beecham Biologicals’ Herpes Simplex candidate vaccine (gD2t-MPL-QS-21), with gD-Al-MPL as control.
208141/014 Completed A double-blind, randomized study to compare, in healthy HSV seronegative subjects, the humoral and cellular immune response of various formulations of herpes simplex candidate vaccines.
208141/015 Completed Study to compare, in healthy HSV seronegative and HSV seropositive subjects, the humoral and cellular immune response of herpes simplex candidate vaccines containing gD from two different cell lines and using gD-Alum as control
208141/016 Completed Study to evaluate the safety of GSK Biologicals’ Herpes Simplex candidate vaccine (gD2t) with MPL in HSV seropositive or seronegative subjects without genital herpes disease
208141/017 Completed Safety of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL & its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease Study Listed on ClinicalStudyDataRequest.com
208141/019 Completed A study comparing the immunogenicity of gD Alum MPL candidate herpes vaccines containing gD produced from 2 different cell lines (CHO DHFR and CHO K1) and at different gD CHO K1 production scales (300L and 600L) in healthy adult HSV seronegative subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.